Two-year data show a continued survival advantage for self-expanding transcatheter aortic valve replacement (TAVR) over standard surgery in high-risk patients with severe aortic stenosis, according to new research.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/IjjjjChywKI/150316102104.htm
Self-expanding TAVR widens advantage over surgery at two years
16 marzo 2015
Volver